888.339.0588
HOME | ABOUT | PHYSICIANS | LOCATION | APPOINTMENT | PATIENTS | RESOURCES | ALUMNI | CONTACT

Home » Resources » Research

 

RESEARCH


In an effort to provide our patients and their families with the best possible care, all patients treated at the Florida Center for Prostate Care are closely monitored by our dedicated team and tracked in our computerized database. In addition, all seed implants are carefully analyzed for quality assurance.

We continually strive to offer our patients the newest and most innovative cancer treatments available by participating in both national and regional research trials. This includes participation with:

  • National Cancer Institute

  • Radiation Therapy Oncology Group

  • Eastern Co-Operative Oncology Group

  • N.S.A.B.P.

  • Southwest Oncology Group

  • Numerous Pharmaceutical Companies

Divider

Medical Research

 

 
NAME:
 * required
EMAIL:
 * required
PHONE:
QUESTIONS/COMMENTS:
YES
I give Florida Center for Prostate Care permission to communicate medical information with me via email:

Schedule a Consultation
Request a Free Book
PSA Facts
Patien Area
Traveling Patient's Assitance

Screening for Prostate Cancer US Preventive Services Task Force Recommendation Statement

Importance

In the United States, the lifetime risk of being diagnosed with prostate cancer is approximately 13%, and the lifetime risk of dying of prostate cancer is 2.5%. The median age of death from prostate cancer is 80 years. Many men with prostate cancer never experience symptoms and, without screening, would never know they have the disease. African American men and men with a family history of prostate cancer have an increased risk of prostate cancer compared with other men.

Objective

To update the 2012 US Preventive Services Task Force (USPSTF) recommendation on prostate-specific antigen (PSA)–based screening for prostate cancer.

Evidence Review

The USPSTF reviewed the evidence on the benefits and harms of PSA-based screening for prostate cancer and subsequent treatment of screen-detected prostate cancer. The USPSTF also commissioned a review of existing decision analysis models and the overdiagnosis rate of PSA-based screening. The reviews also examined the benefits and harms of PSA-based screening in patient subpopulations at higher risk of prostate cancer, including older men, African American men, and men with a family history of prostate cancer.

Findings

Adequate evidence from randomized clinical trials shows that PSA-based screening programs in men aged 55 to 69 years may prevent approximately 1.3 deaths from prostate cancer over approximately 13 years per 1000 men screened. Screening programs may also prevent approximately 3 cases of metastatic prostate cancer per 1000 men screened. Potential harms of screening include frequent false-positive results and psychological harms. Harms of prostate cancer treatment include erectile dysfunction, urinary incontinence, and bowel symptoms. About 1 in 5 men who undergo radical prostatectomy develop long-term urinary incontinence, and 2 in 3 men will experience long-term erectile dysfunction. Adequate evidence shows that the harms of screening in men older than 70 years are at least moderate and greater than in younger men because of increased risk of false-positive results, diagnostic harms from biopsies, and harms from treatment. The USPSTF concludes with moderate certainty that the net benefit of PSA-based screening for prostate cancer in men aged 55 to 69 years is small for some men. How each man weighs specific benefits and harms will determine whether the overall net benefit is small. The USPSTF concludes with moderate certainty that the potential benefits of PSA-based screening for prostate cancer in men 70 years and older do not outweigh the expected harms.

Conclusions & Recommendations

For men aged 55 to 69 years, the decision to undergo periodic PSA-based screening for prostate cancer should be an individual one and should include discussion of the potential benefits and harms of screening with their clinician. Screening offers a small potential benefit of reducing the chance of death from prostate cancer in some men. However, many men will experience potential harms of screening, including false-positive results that require additional testing and possible prostate biopsy; overdiagnosis and overtreatment; and treatment complications, such as incontinence and erectile dysfunction. In determining whether this service is appropriate in individual cases, patients and clinicians should consider the balance of benefits and harms on the basis of family history, race/ethnicity, comorbid medical conditions, patient values about the benefits and harms of screening and treatment-specific outcomes, and other health needs. Clinicians should not screen men who do not express a preference for screening. (C recommendation) The USPSTF recommends against PSA-based screening for prostate cancer in men 70 years and older. (D recommendation)

Full Study: CLICK HERE


Association Between Treatment at a High-Volume Facility and Improved Survival for Radiation-Treated Men With High-Risk Prostate Cancer

Yu-Wei Chen, MD, MS, Brandon A. Mahal, MD, Vinayak Muralidhar, MSc, Michelle Nezolosky, BA, Clair J. Beard, MD, Robert B. Den, MD, Felix Y. Feng, MD, Karen E. Hoffman, MD, MPH, MHSc, Neil E. Martin, MD, MPH, Peter F. Orio, DO, MS, Paul L. Nguyen, MD

Purpose

Although the association between higher hospital volume and improved outcomes has been well-documented in surgery, there is little data about whether this effect exists for radiation-treated patients. We investigated whether treatment at a radiation facility that treats a high volume of prostate cancer patients is associated with improved survival for men with high-risk prostate cancer.

Methods and Materials

We used the National Cancer Database (NCDB) to identity patients diagnosed with prostate cancer from 2004 to 2006. The radiation case volume (RCV) of each hospital was based on its number of radiation-treated prostate cancer patients. We used propensity-score based analysis to compare the overall survival (OS) of high-risk prostate cancer patients in high versus low RCV hospitals. Primary endpoint is overall survival. Covariates adjusted for were tumor characteristics, sociodemographic factors, radiation type, and use of androgen deprivation therapy (ADT).

Results

A total of 19,565 radiation-treated high-risk patients were identified. Median follow-up was 81.0 months (range: 1-108 months). When RCV was coded as a continuous variable, each increment of 100 radiation-managed patients was associated with improved OS (adjusted hazard ratio [AHR]: 0.97; 95% confidence interval [CI]: 0.95-0.98; P<.0001) after adjusting for known confounders. For illustrative purposes, when RCV was dichotomized at the 80th percentile (43 patients/year), high RCV was associated with improved OS (7-year overall survival 76% vs 74%, log-rank test P=.0005; AHR: 0.91, 95% CI: 0.86-0.96, P=.0005). This association remained significant when RCV was dichotomized at 75th (37 patients/year), 90th (60 patients/year), and 95th (84 patients/year) percentiles but not the 50th (19 patients/year).

Conclusions

Our results suggest that treatment at centers with higher prostate cancer radiation case volume is associated with improved OS for radiation-treated men with high-risk prostate cancer.

Full Study: CLICK HERE

Divider

Medical Physics Logo

Divider

Treatment Methods for Early and Advanced Prostate Cancer

Divider

Prostate brachytherapy preserves erectile function:

Divider

Back to top

PubMed

Vargas C, Swartz D, Vashi A, Blasser M, Kasareian A, Cesaretti J, Kiley K, Terk M. Long-Term Outcomes and Prognostic Factors in Patients Treated with Intraoperatively Planned Prostate Brachytherapy. Brachytherapy. 2013 Mar-Apr;12(2):120-5

Terk M, Vargas C, Cesaretti J, Swartz D, Blasser M , Vashi A, Kasraeian A, Koziol J, Kiley K. Excellent Long-Term Outcomes with Prostate Brachytherapy in Young Men Less Than 55 Years Old. Brachytherapy. 2013; 12 (2), Suppl 1, S12

Swartz D, Vargas C, Terk M, Vashi A. Salvage Palladium Brachytherapy for Local Failure after Initial External Radiotherapy for Prostate Cancer. Oral Presentation. American Urological Association - Annual Meeting. May 5, 2013

Stoyanova R, Pahlajani NH, Egleston BL, Buyyounouski MK, Chen DY, Horwitz EM, Pollack A. The impact of dose-escalated radiotherapy plus androgen deprivation for prostate cancer using 2 linked nomograms. Cancer. 2013 Mar 1; 119(5):1080-8.

Pahlajani N, Ruth KJ, Buyyounouski MK, Chen DY, Horwitz EM, Hanks GE, Price RA, Pollack A. Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate cancer. Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1949-56

Kerns S, Stock R, Stone N, Blacksburg S, Rath L, Vega A, Fachal L, Gómez-Caamaño A, De Ruysscher D, Lammering G, Parliament M, Blackshaw M, Sia M, Cesaretti J, Terk M, Hixson R, Rosenstein B, Ostrer H. Genome-wide association study identifies a region on chromosome 11q14.3 associated with late rectal bleeding following radiation therapy for prostate cancer. Radiotherapy and Oncology (in press 2013)

Kerns SL, Stock R, Stone N, Buckstein M, Shao Y, Campbell C, Rath L, De Ruysscher D, Lammering G, Hixson R, Cesaretti J, Terk M, Ostrer H, Rosenstein BS. A 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of erectile dysfunction following radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):e21-8

Burri R, Ng J, Horowitz D, Cesaretti J, Terk M, Kao J, Thompson D , Stephens T, Chao KS, Brenner D, Shuryak I . Rectal balloons and the risk of secondary rectal cancer after combined modality prostate radiation. World Congress of Brachytherapy 2012, Barcelona, Spain, May 10-12, 2012

Burri R, Ng J, Horowitz D, Cesaretti J, Kao J, Thompson D, Stephens T, Chao KS, Brenner D, Shuryak I. Rectal Balloons and the Risk of Secondary Rectal Malignancy After IMRT for Prostate Cancer. ASTRO 2012, Boston, October 28-31, 2012

Burri R, Ng J, Horowitz D, Cesaretti J, Kao J, Thompson D, Stephens T, Chao KS, Brenner D, Shuryak I. Rectal balloons and secondary rectal cancer risk after 3D-conformal radiation for prostate cancer. ESTRO 31, 2012, Barcelona, Spain, May 9-13, 2012

Predictors of metastatic disease afterprostate brachytherapy. Forsythe K, Burri R, Stone N, Stock RG. Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):645-52.Epub 2011 Dec 2. PubMed PMID: 22137025.

Long-term outcome and toxicity ofsalvage brachytherapy for local failure after initial radiotherapy for prostatecancer. Burri RJ, Stone NN, Unger P, Stock RG. Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1338-44. PubMed PMID:20138442.

Update on prostate brachytherapy: long-term outcomes and treatment-related morbidity. Kao J, Cesaretti JA, Stone NN, Stock RG. Curr Urol Rep. 2011 Jun;12(3):237-42. Review. PMID: 21399887

Young men have equivalent biochemical outcomes compared with older men after treatment with brachytherapy for prostate cancer. Burri RJ, Ho AY, Forsythe K, Cesaretti JA, Stone NN, Stock RG. Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1315-21. Epub 2010 Jan 13. PMID: 20044216

Does neoadjuvant hormonal therapy improve urinary function when given to men with large prostates undergoing prostate brachytherapy? Stone NN, Marshall DT, Stone JJ, Cesaretti JA, Stock RG. J Urol. 2010 Feb;183(2):634-9. Epub 2009 Dec 16. PMID: 20018308. Do high radiation doses in locally advanced prostate cancer patients treated with 103Pd implant plus external beam irradiation cause increased urinary, rectal, and sexual morbidity? Stone NN, Cesaretti JA, Rosenstein B, Stock RG. Brachytherapy. 2010 Apr-Jun;9(2):114-8. Epub 2009 Oct 30. PMID: 19879812

Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes. Stone NN, Stock RG, Cesaretti JA, Unger P. Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):355-60. Epub 2009 Jul 23. PMID: 19632069

Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy. Stock RG, Cesaretti JA, Hall SJ, Stone NN. BJU Int. 2009 Dec;104(11):1631-6. Epub 2009 Jun 2. PMID: 19493260

Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy. Ho AY, Burri RJ, Cesaretti JA, Stone NN, Stock RG. Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):16-22. Epub 2009 Mar 14. PMID: 19289266

Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy. Stock RG, Klein TJ, Cesaretti JA, Stone NN. Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):753-8. Epub 2008 Dec 10. PMID: 19084351

There is no correlation between erectile dysfunction and dose to penile bulb and neurovascular bundles following real-time low-dose-rate prostate brachytherapy. Solan AN, Cesaretti JA, Stone NN, Stock RG. Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1468-74. Epub 2008 Oct 14. PMID: 18922652

Distant and local recurrence in patients with biochemical failure after prostate brachytherapy. Stock RG, Cesaretti JA, Unger P, Stone NN. Brachytherapy. 2008 Jul-Sep;7(3):217-22. PMID: 18635024

Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer. Burri RJ, Stock RG, Cesaretti JA, Atencio DP, Peters S, Peters CA, Fan G, Stone NN, Ostrer H, Rosenstein BS. Radiat Res. 2008 Jul;170(1):49-59. PMID: 18582155

(125)I monotherapy using D90 implant doses of 180 Gy or greater. Kao J, Stone NN, Lavaf A, Dumane V, Cesaretti JA, Stock RG. Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):96-101. Epub 2007 Nov 5. PMID: 17980505

Brachytherapy for the treatment of prostate cancer. Cesaretti JA, Stone NN, Skouteris VM, Park JL, Stock RG. Cancer J. 2007 Sep-Oct;13(5):302-12. Review. PMID: 17921729

TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy. Peters CA, Stock RG, Cesaretti JA, Atencio DP, Peters S, Burri RJ, Stone NN, Ostrer H, Rosenstein BS. Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):752-9. Epub 2007 Aug 8. PMID: 17689884

Effect of low dose-rate prostate brachytherapy on the sexual health of men with optimal sexual function before treatment: analysis at > or = 7 years of follow-up. Cesaretti JA, Kao J, Stone NN, Stock RG. BJU Int. 2007 Aug;100(2):362-7. PMID: 17617140

A genetically determined dose-volume histogram predicts for rectal bleeding among patients treated with prostate brachytherapy. Cesaretti JA, Stock RG, Atencio DP, Peters SA, Peters CA, Burri RJ, Stone NN, Rosenstein BS. Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1410-6. Epub 2007 May 9. PMID: 17490827

Is seminal vesicle implantation with permanent sources possible? A dose-volume histogram analysis in patients undergoing combined 103Pd implantation and external beam radiation for T3c prostate cancer. Ho AY, Burri RJ, Jennings GT, Stone NN, Cesaretti JA, Stock RG. Brachytherapy. 2007 Jan-Mar;6(1):38-43. PMID: 17284384

Assessment of postbrachytherapy sexual function: a comparison of the IIEF-5 and the MSEFS. Zagar TM, Stock RG, Cesaretti JA, Stone NN. Brachytherapy. 2007 Jan-Mar;6(1):26-33. PMID: 17284382

Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control. Stock RG, Ho A, Cesaretti JA, Stone NN. Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):389-94. PMID: 16965991

Low-dose rate prostate brachytherapy is well tolerated in patients with a history of inflammatory bowel disease. Peters CA, Cesaretti JA, Stone NN, Stock RG. Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):424-9. Epub 2006 Aug 2. PMID: 16887295

Genetic predictors of adverse radiotherapy effects: the Gene-PARE project. Ho AY, Atencio DP, Peters S, Stock RG, Formenti SC, Cesaretti JA, Green S, Haffty B, Drumea K, Leitzin L, Kuten A, Azria D, Ozsahin M, Overgaard J, Andreassen CN, Trop CS, Park J, Rosenstein BS. Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):646-55. PMID: 16751059

Adjuvant radiation with modern techniques is the standard of care for stage III thymoma. Cesaretti JA. Ann Thorac Surg. 2006 Mar;81(3):1180-1; author reply 1181-2. No abstract available. PMID: 16488766

ATM sequence variants and risk of radiation-induced subcutaneous fibrosis after postmastectomy radiotherapy. Andreassen CN, Overgaard J, Alsner J, Overgaard M, Herskind C, Cesaretti JA, Atencio DP, Green S, Formenti SC, Stock RG, Rosenstein BS. Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):776-83. Epub 2005 Dec 9. PMID: 16338099

Disease-specific survival following the brachytherapy management of prostate cancer. Stock RG, Cesaretti JA, Stone NN. Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):810-6. Epub 2005 Nov 23. PMID: 16309852

Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. Stock RG, Stone NN, Cesaretti JA, Rosenstein BS. Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):527-33. Epub 2005 Oct 19. PMID: 16242258

ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer. Cesaretti JA, Stock RG, Lehrer S, Atencio DA, Bernstein JL, Stone NN, Wallenstein S, Green S, Loeb K, Kollmeier M, Smith M, Rosenstein BS. Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):196-202. PMID: 15629612

Does prior transurethral resection of prostate compromise brachytherapy quality: a dosimetric analysis. Cesaretti JA, Stone NN, Stock RG. Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):648-53. PMID: 15380602

Combined modality treatment in the management of high-risk prostate cancer. Stock RG, Cahlon O, Cesaretti JA, Kollmeier MA, Stone NN. Int J Radiat Oncol Biol Phys. 2004 Aug 1;59(5):1352-9. PMID: 15275720

Urinary symptom flare following I-125 prostate brachytherapy. Cesaretti JA, Stone NN, Stock RG. Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1085-92. PMID: 12829146

Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications. Stock RG, Stone NN, Cesaretti JA. Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):448-53. PMID: 12738319

Intraprostatic fiducials for localization of the prostate gland: The distance between markers as a surrogate for marker stability. Kupelian PA, Willoughby TR, Meeks SL, Forbes A, Wagner TH, Maach M, Langen KM. 2005 Aug 1. PMID: 16029784

Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. Terk MD, Stock RG, Stone NN. 1998 Oct. PMID: 9751358

High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer. Martinez AA, Demanes J, Vargas C, Schour L, Ghilezan M, Gustafson GS. Am J Clin Oncol. 2010 Oct;33(5):481-8. PMID:19952715

In vivo verification of proton beam path by using post-treatment PET/CT imaging. Hsi WC, Indelicato DJ, Vargas C, Duvvuri S, Li Z, Palta J. Med Phys. 2009 Sep;36(9):4136-46. PMID:19810487

Cine-magnetic resonance imaging assessment of intrafraction motion for prostate cancer patients supine or prone with and without a rectal balloon. Vargas C, Saito AI, Hsi WC, Indelicato D, Falchook A, Zengm Q, Oliver K, Keole S, Dempsey J. Am J Clin Oncol. 2010 Feb;33(1):11-6. PMID:19730351

Dosimetric study of pelvic proton radiotherapy for high-risk prostate cancer. Chera BS, Vargas C, Morris CG, Louis D, Flampouri S, Yeung D, Duvvuri S, Li Z, Mendenhall NP. Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):994-1002. Epub 2009 Jul 18. PMID:19619961

Proton therapy for prostate cancer treatment employing online image guidance and an action level threshold. Vargas C, Falchook A, Indelicato D, Yeung A, Henderson R, Olivier K, Keole S, Williams C, Li Z, Palta J. Am J Clin Oncol. 2009 Apr;32(2):180-6. PMID:19307953

Dosimetric uncertainty in prostate cancer proton radiotherapy. Lin L, Vargas C, Hsi W, Indelicato D, Slopsema R, Li Z, Yeung D, Horne D, Palta J. Med Phys. 2008 Nov;35(11):4800-7. PMID:19070212

Dose-volume differences for computed tomography and magnetic resonance imaging segmentation and planning for proton prostate cancer therapy. Yeung AR, Vargas CE, Falchook A, Louis D, Olivier K, Keole S, Yeung D, Mendenhall NP, Li Z. Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1426-33. Epub 2008 Aug 30. PMID:18762391

Image guidance based on prostate position for prostate cancer proton therapy. Vargas C, Wagner M, Indelicato D, Fryer A, Horne D, Chellini A, McKenzie C, Lawlor P, Mahajan C, Li Z, Lin L, Keole S. Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1322-8. Epub 2008 May 28. PMID:18472365

Proton therapy coverage for prostate cancer treatment. Vargas C, Wagner M, Mahajan C, Indelicato D, Fryer A, Falchook A, Horne D, Chellini A, McKenzie C, Lawlor P, Li Z, Lin L, Keole S. Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1492-501. PMID:18374228

Rectal dose-volume differences using proton radiotherapy and a rectal balloon or water alone for the treatment of prostate cancer. Vargas C, Mahajan C, Fryer A, Indelicato D, Henderson RH, McKenzie C, Horne D, Chellini A, Lawlor P, Li Z, Oliver K, Keole S. Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1110-6. PMID:17967305

Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose-volume analysis of a phase II dose-escalation study. Harsolia A, Vargas C, Yan D, Brabbins D, Lockman D, Liang J, Gustafson G, Vicini F, Martinez A, Kestin LL. Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1100-9. PMID:17967304

Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer. Vargas C, Fryer A, Mahajan C, Indelicato D, Horne D, Chellini A, McKenzie C, Lawlor P, Henderson R, Li Z, Lin L, Olivier K, Keole S. Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):744-51. Epub 2007 Sep 27. PMID:17904306

Incidence of late rectal bleeding in high-dose conformal radiotherapy of prostate cancer using equivalent uniform dose-based and dose-volume-based normal tissue complication probability models. Söhn M, Yan D, Liang J, Meldolesi E, Vargas C, Alber M. Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1066-73. Epub 2007 Jan 26. PMID: 17258870

Matched-pair analysis of prostate cancer patients with a high risk of positive pelvic lymph nodes treated with and without pelvic RT and high-dose radiation using high dose rate brachytherapy. Vargas CE, Demanes J, Boike TP, Barnaba MC, Skoolisariyaporn P, Schour L, Gustafson GS, Gonzalez J, Martinez AA. Am J Clin Oncol. 2006 Oct;29(5):451-7. PMID: 17023778

High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: results of a phase I to II study. Vargas CE, Martinez AA, Boike TP, Spencer W, Goldstein N, Gustafson GS, Krauss DJ, Gonzalez J. Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):416-23. Epub 2006 Jul 31. PMID: 16879929

Clinicopathologic analysis of extracapsular extension in prostate cancer: should the clinical target volume be expanded posterolaterally to account for microscopic extension? Chao KK, Goldstein NS, Yan D, Vargas CE, Ghilezan MI, Korman HJ, Kernen KM, Hollander JB, Gonzalez JA, Martinez AA, Vicini FA, Kestin LL. Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):999-1007. Epub 2006 Jun 5. PMID:16750320

Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity. Vargas C, Yan D, Kestin LL, Krauss D, Lockman DM, Brabbins DS, Martinez AA. Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):141-9. PMID:16111582

A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy. Vargas C, Ghilezan M, Hollander M, Gustafson G, Korman H, Gonzalez J, Martinez A. J Urol. 2005 Sep;174(3):882-7. PMID:16093980

Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime. Martinez AA, Demanes DJ, Galalae R, Vargas C, Bertermann H, Rodriguez R, Gustafson G, Altieri G, Gonzalez J. Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1322-31. PMID:16029788

Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Vargas C, Martinez A, Kestin LL, Yan D, Grills I, Brabbins DS, Lockman DM, Liang J, Gustafson GS, Chen PY, Vicini FA, Wong JW. Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1297-308. Review. PMID:16029785

Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation. Vargas CE, Galalae R, Demanes J, Harsolia A, Meldolesi E, Nürnberg N, Schour L, Martinez A. Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1474-82. Epub 2005 Jun 20. PMID:15964706

Assessment of residual error for online cone-beam CT-guided treatment of prostate cancer patients. Létourneau D, Martinez AA, Lockman D, Yan D, Vargas C, Ivaldi G, Wong J. Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1239-46. PMID:15913917

Limitations in the use of serum prostate specific antigen levels to monitor patients after treatment for prostate cancer. Vicini FA, Vargas C, Abner A, Kestin L, Horwitz E, Martinez A. J Urol. 2005 May;173(5):1456-62. Review. PMID:15821460

Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features. Vargas C, Kestin LL, Weed DW, Krauss D, Vicini FA, Martinez AA. Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):714-24. PMID:15708249

High dose rate brachytherapy in the treatment of prostate cancer. Vicini F, Vargas C, Gustafson G, Edmundson G, Martinez A. World J Urol. 2003 Sep;21(4):220-8. Epub 2003 Aug 5. Review. PMID:12905008

The role of high-dose rate brachytherapy in locally advanced prostate cancer. Vicini FA, Vargas C, Edmundson G, Kestin L, Martinez A. Semin Radiat Oncol. 2003 Apr;13(2):98-108. Review. PMID: 12728439

Back to top

Divider

American Society for Radiation Oncology

Long-Term Prostate Brachytherapy Outcomes With 10 Years Of Minimum Follow-up

Long Term Biochemical Control And Survival In High-risk Prostate Cancer Patients Treated With Seed Implant Based Therapy

Salvage Pd-103 Seed Implantation In The Treatment Of Locally Recurrent Prostate Cancer Previously Treated With External Beam Radiation Therapy

Identification Of Optimal Patients For Salvage Prostate Seed Implantation In The Treatment Of Locally Recurrent Cancer Previously Treated With External Radiation Therapy

Improving the Therapeutic Ratio of Prostate Brachytherapy: Dose Escalation in I-125 Prostate Implants

Radiation Dose, Not Treatment Regimen, Is the Most Significant Predictor of Biochemical Control in Patients with Intermediate Risk Prostate Cancer

Use of the Surveyor Nuclease Assay to Identify Genetic Variants Predictive for the Development of Adverse Radiotherapy Effects

Prognostic Significance of the 5-year PSA Value for Predicting Prostate Cancer Recurrence Following Brachytherapy

Comparisons of PSA Failure Definitions Following Trimodality Therapy for Intermediate to High-Risk Prostate Cancer

Dose Response Study of Pd-103 Prostate Seed Implantation

Correlation Between Erectile Dysfunction and Dose to Penile Bulb and Neurovascular Bundles Following Prostate Brachytherapy

The Effect of Family History on Outcome in Patients Treated with Low-dose Rate Brachytherapy for Clinically Localized Prostate Cancer

Combined Low Dose Rate Brachytherapy and External Beam Radiotherapy Result in a Favorable Acute Urinary Symptom Profile Relative to Brachytherapy Monotherapy at the Same Biological Equivalent Dose (BED)

Local Control Following Permanent Prostate Brachytherapy (PPB): Effect of High Biologic Effective Dose on Biopsy Results and Oncologic Outcomes

Long term Outcomes for Patients with Gleason Scores 8-10 Prostate Cancer Treated with Combination Brachytherapy, External Beam Irradiation and Hormonal Therapy

A Pretreatment PSA Level of 7 to 10 Ng/ml is an Independent Predictor of Adverse Biochemical Disease Free Survival among Low Risk Prostate Cancer Patients Treated with I-125 Brachytherapy

Defining the Risk of Developing Grade 2 Proctitis Following Combined Modality Therapy using a Rectal Dose-volume Histogram Analysis and Biologic Equivalent Dose

The Relationship of Erectile Dysfunction and Rectal Bleeding to Radiation Dose Following Real-time Low-dose Rate Prostate Brachytherapy

Hormone use and Total Biological Equivalent Dose (BED) are Associated with Shorter PSA Doubling Times in Prostate Cancer Patients Treated with Radiotherapy who Experience a PSA Failure

ATM Sequence Variants are Predictive of Adverse Radiotherapy Response Amond Patients Treated for Prostate Cancer

Defining the Risk of Developing Grade 2 Proctitis Following Combined Modality Therapy using a Rectal Dose-volume Histogram Analysis and Biologic Equivalent Dose

The Relationship of Erectile Dysfunction and Rectal Bleeding to Radiation Dose Following Real-time Low-dose Rate Prostate Brachytherapy

Hormone use and Total Biological Equivalent Dose (BED) are Associated with Shorter PSA Doubling Times in Prostate Cancer Patients Treated with Radiotherapy who Experience a PSA Failure

ATM Sequence Variants are Predictive of Adverse Radiotherapy Response Amond Patients Treated for Prostate Cancer

Vardenafil Is More Efficacious Than Tadalafil For Patient's Who Requested An Alternative To Sildenafil Following Prostate Brachytherapy.

Back to top